Abstract
Sarcoidosis is a granulomatous multiorgan diseases with an unknown etiology, with the predominant lung involvement. Immunosuppressive agents such as corticosteroids, methotrexate, azathioprinum, ciclosporinum A, chlorambucil, cyclophosphamide, hydroxychlorochinum, indomethacin, pentoxyfillinum, thalidomide, leflunomidum, and adalimumab, or infliximab have been used in its treatment. It should be emphasized that the Summary of Products Characteristics (SPC) of these drugs does not specifically recommend their use in the therapy for sarcoidosis. That makes the application of the drugs in sarcoidosis an off-label use, which is not formally accepted by the authorities but is supported by medical bibliography or recommendations given by scientific bodies. Thus the off-label drugs raise legal, but also ethical and medical problems. The dosing regimen and the required duration of therapy for sarcoidosis are missing. In effect the therapy usually follows the recommendations from the American and European Respiratory Societies (ATS/ERS), based on the long-term medical research. The American Food and Drug Administration recognizes the existence of the off-label use. European legislations do not precisely specify the rules for the admissibility of the off-label use. The doctrine of law assumes that the off-label use constitutes a medical experiment. Therefore, the commencement of therapy with such drugs requires patients’ informed consent, which must be kept along with other medical records. Insufficient knowledge of the legal regulations may result in civil and professional liability of a physician supervising the therapy of a sarcoidosis patient, especially in case of adverse effects.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
American Society of Clinical Oncology (ASCO). (2006). Reimbursement for cancer treatment: Coverage of off-label drug indications. Journal of Clinical Oncology, 24, 3206–3208.
American Thoracic Society (ATS). (1999). Statement on sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 160, 736–755.
Baughman, R. P., Costabel, U., & du Bois, R. M. (2008). Treatment of sarcoidosis. Clinics in Chest Medicine, 29, 533–548.
Bernardi, A., & Pegoraro, R. (2008). The ethics of off-label use of drugs: Oncology pharmacy in Italy. Journal of Clinical Pharmacy and Therapeutics, 33, 95–99.
Brockmeyer, N. H., Brucklacher, U., Potthoff, A., & Reich-Schupke, S. (2009). Off-label use in dermatology in Germany: What has changed since 2004? Journal der Deutschen Dermatologischen Gesellschaft, 7, 938–945.
Brunne, V., Mertins, G., Reimann, G., & Brockmeyer, N. H. (2004). Off-label use in dermatological practice. The conflict between professional duty and legal requirements. Der Hautarzt, 55, 727–734.
Casali, P. G. (2007). The off label use of drugs in oncology: A position paper by the European Society for Medical Oncology. Annals of Oncology, 18, 1923–1925.
Chen, M., Doherty, S. D., & Hsu, S. (2010). Innovative uses of thalidomide. Dermatologia Clinica, 28, 577–586.
Coker, R. K. (2009). Management strategies for pulmonary sarcoidosis. Therapeutics and Clinical Risk Management, 5, 575–584.
Devita, V. T. (2009). Off-label use of approved drugs. Nature Reviews. Clinical Oncology, 6, 181.
Ehlers, A. P. F., & Bitter, H. (2003). Der off-label use. Pharma Recht, 3, 76–78.
Gazarian, M., Kelly, M., & McPhee, J. R. (2006). Off-label use of medicines: Consensus recommendations for evaluating appropriateness. The Medical Journal of Australia, 185, 544–548.
Gillick, M. R. (2009). Controlling off-label medication use. Annals of Internal Medicine, 150, 344–347.
Henry, V. (1999). Off-label prescribing legal implications. The Journal of Legal Medicine, 20, 365–383.
Higgins, L. C. (1988). Off-label Rx. Insurers starting to balk. Medical World News, 29, 22–24.
Jacqz-Aigrain, E. (2011). Drug policy in Europe. Research and funding in neonates: Current challenges future perspectives new opportunities. Early Human Development, 87(Suppl. 1), S27–S30.
Pavis, H., & Wilcock, A. (2001). Prescribing of drugs for use outside their licence in palliative care. British Medical Journal, 323, 484.
Poole, S. G., & Dooley, M. J. (2004). Off-label prescribing in oncology. Supportive Care in Cancer, 12, 302–305.
Rothberg, M. (2005). Ethical Challenges in Medicine. In M. L. Pava & P. Primeaux (Eds.), Crisis and opportunity in the professions (Research in ethical issues in organizations) (Vol. 6, pp. 21–41). Bradford: Emerald Group Publishing Limited.
Schutt, A. C., Wendy, M. B., & Judson, M. A. (2010). Pharmacotherapy for pulmonary sarcoidosis. A delphi consensus study. Respiratory Medicine, 104, 717–723.
World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended thereafter.
Zimmermann, A., & Zimmermann, R. (2008). Off-label use of medicinal products – Legal aspects. Farmacja Polska, 64, 108–111.
Conflicts of interest: The authors declare no conflicts of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this paper
Cite this paper
Zimmermann, A., Dubaniewicz, A., Slominski, J.M. (2013). Pharmacotherapy for Sarcoidosis: An Example of an Off-Label Procedure. In: Pokorski, M. (eds) Respiratory Regulation - Clinical Advances. Advances in Experimental Medicine and Biology, vol 755. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4546-9_32
Download citation
DOI: https://doi.org/10.1007/978-94-007-4546-9_32
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-4545-2
Online ISBN: 978-94-007-4546-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)